The Massachusetts-based Peddock Lc has invested 0.63% in Gilead Sciences, Inc. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company's stock worth $632,000 after buying an additional 39 shares during the last quarter. This represents an increase of 2% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks. About 4.77 million shares traded. Commvault Systems, Inc. (CVLT) has risen 28.52% since December 7, 2016 and is uptrending. It has outperformed by 39.22% the S&P500.
On average, analysts expect that Gilead Sciences will report full year earnings of $7.88 per share for the current fiscal year, with EPS estimates ranging from $6.86 to $8.31. National Planning Corp sold 5,403 shares as Gilead Sciences Inc (GILD)'s stock declined 8.05%. The Becker Capital Management Inc holds 687,979 shares with $48.70M value, up from 546,419 last quarter.
MML Investors Services LLC increased its holdings in shares of Gilead Sciences, Inc.
The stock decreased 2.61% or $0.04 during the last trading session, reaching $1.49. About 5.04 million shares traded. Gilead Sciences, Inc. The stock has a market cap of $95,736.46, a price-to-earnings ratio of 7.65, a price-to-earnings-growth ratio of -1.23 and a beta of 1.13. It has underperformed by 66.82% the S&P500.
Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 33% are positive. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Gilead Sciences by 29.3% in the second quarter. Atria Invs Ltd Llc stated it has 0.07% in Gilead Sciences, Inc. Credit Suisse Group set a $79.00 price objective on shares of Gilead Sciences and gave the company a "buy" rating in a research report on Monday, August 28th. (NASDAQ:GILD) earned "Strong Buy" rating by Jyske Bank on Thursday, September 10. The company was maintained on Monday, August 21 by Cowen & Co. The stock has a consensus rating of "Buy" and a consensus target price of $85.22. (NASDAQ:GILD) has "Buy" rating given on Monday, October 16 by Robert W. Baird.
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. (NASDAQ:GILD) has "Buy" rating given on Wednesday, October 5 by Jefferies. The company was maintained on Friday, October 6 by Morgan Stanley. The company was maintained on Tuesday, June 27 by RBC Capital Markets. On Tuesday, March 15 the stock rating was maintained by Jefferies with "Hold". Carlton Hofferkamp And Jenks Wealth Mngmt Limited Liability has invested 0.38% in Honeywell International Inc. It also reduced Abiomed Inc (NASDAQ:ABMD) stake by 10,898 shares and now owns 106,150 shares. The investor is now holding 27,711,666 shares thanks to an increase of 4,674,363 new shares in their portfolio. Its up 0.33, from 1.3 in 2017Q1. Earlier this month, Gregg Alton, the EVP Comm&Acs ALA, Corp&Med Aff of GILD sold 15,000 shares for a total of $1,119,414. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.13 by $0.14.
The Return on Invested Capital (aka ROIC) for Gilead Sciences, Inc. (NASDAQ:GILD) by 16.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The outstanding shares for Gilead Sciences, Inc.is 1306 with a shares float of 1295.8. Ing Groep Nv has invested 0.59% in Gilead Sciences, Inc. (NASDAQ:RAVE) news were published by: Prnewswire.com which released: "RAVE Restaurant Group, Inc". Atlantic Trust Grp Inc Inc Limited Liability Company, Georgia-based fund reported 61,815 shares. Lawson Kroeker Management Ne holds 120,922 shares or 2.87% of its portfolio. Kingfisher Cap Limited Liability Co has 3,000 shares for 0.14% of their portfolio. First Foundation Advsrs reported 108,309 shares. Clinton Gru has 0.42% invested in Gilead Sciences, Inc. The option since executed brings Martin ownership to 3 million shares. Finally, Sterling Investment Advisors Ltd. acquired a new position in shares of Gilead Sciences during the second quarter worth $184,000.
Investors sentiment decreased to 0.96 in Q2 2017. Its up 0.02, from 0.91 in 2017Q1. 104 funds opened positions while 426 raised stakes. (NYSE:HON) to report earnings on January, 26. Svcs Automobile Association owns 12,050 shares. The shares went up by 1.26% in value last month. Winslow Evans And Crocker reported 1,752 shares or 0% of all its holdings. 725 are owned by Davidson Invest Advsr. (NYSE:HON). Meritage Portfolio Management reported 0.02% stake. Dekabank Deutsche Girozentrale reported 606,439 shares or 0.74% of all its holdings. Bluecrest Capital Mngmt Ltd accumulated 0.27% or 51,782 shares. Mufg Americas Corp reported 0.86% stake. Raymond James & Associate, Florida-based fund reported 20,541 shares. Ray Gerald L Assoc Limited holds 0.14% or 7,101 shares in its portfolio. (NASDAQ:GILD) were released by: Bizjournals.com and their article: "With HIV infection rates soaring in South, Gilead pledges $100 million" published on December 04, 2017 as well as Bizjournals.com's news article titled: "Gilead Sciences, University of Houston and others launch $100M initiative to ..." with publication date: December 05, 2017.